BC Extra | Jul 17, 2018
Company News

Management tracks: Silence, Apeiron

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...
BC Week In Review | Mar 23, 2018
Clinical News

Anthera discontinues development of Sollpura

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) discontinued development of Sollpura liprotamase (LY3031642) after the candidate missed the primary endpoint in the Phase III RESULT trial to treat exocrine pancreatic insufficiency due to cystic fibrosis. The company said...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jun 16, 2017
Clinical News

Anthera starts Phase III RESULT trial of Sollpura

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) began the Phase III RESULT trial to evaluate oral Sollpura liprotamase (LY3031642) for 4 weeks to treat exocrine pancreatic insufficiency due to cystic fibrosis (CF). Top-line data from the trial are...
BioCentury | Apr 7, 2017
Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
BC Week In Review | Mar 15, 2017
Financial News

Anthera completes follow-on

On March 14, Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) raised $15 million through the sale of 30 million shares at $0.50 in a follow-on underwritten by H.C. Wainwright. Investors also received five-year warrants to purchase up to...
BC Week In Review | Jan 6, 2017
Clinical News

Sollpura: Ph III SOLUTION data

Top-line data from the open-label, international Phase III SOLUTION trial in 129 patients showed that oral Sollpura missed the primary endpoint of non-inferiority to oral porcine-derived pancreatic enzyme replacement therapy (PERT) in the change from...
BC Week In Review | Dec 1, 2016
Clinical News

Blisibimod: Ph III CHABLIS-SC1 data

Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly subcutaneous blisibimod missed the primary endpoint of a greater proportion of...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BC Week In Review | Sep 12, 2016
Financial News

Anthera completes private placement of convertible preferred stock and warrants

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif.   Business: Autoimmune, Gastrointestinal, Renal   Date completed: 2016-09-08   Type: Private placement of convertible preferred stock and warrants   Raised: $17 million   Shares: 17,000   Price: $1,000...
Items per page:
1 - 10 of 171
BC Extra | Jul 17, 2018
Company News

Management tracks: Silence, Apeiron

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...
BC Week In Review | Mar 23, 2018
Clinical News

Anthera discontinues development of Sollpura

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) discontinued development of Sollpura liprotamase (LY3031642) after the candidate missed the primary endpoint in the Phase III RESULT trial to treat exocrine pancreatic insufficiency due to cystic fibrosis. The company said...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jun 16, 2017
Clinical News

Anthera starts Phase III RESULT trial of Sollpura

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) began the Phase III RESULT trial to evaluate oral Sollpura liprotamase (LY3031642) for 4 weeks to treat exocrine pancreatic insufficiency due to cystic fibrosis (CF). Top-line data from the trial are...
BioCentury | Apr 7, 2017
Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
BC Week In Review | Mar 15, 2017
Financial News

Anthera completes follow-on

On March 14, Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) raised $15 million through the sale of 30 million shares at $0.50 in a follow-on underwritten by H.C. Wainwright. Investors also received five-year warrants to purchase up to...
BC Week In Review | Jan 6, 2017
Clinical News

Sollpura: Ph III SOLUTION data

Top-line data from the open-label, international Phase III SOLUTION trial in 129 patients showed that oral Sollpura missed the primary endpoint of non-inferiority to oral porcine-derived pancreatic enzyme replacement therapy (PERT) in the change from...
BC Week In Review | Dec 1, 2016
Clinical News

Blisibimod: Ph III CHABLIS-SC1 data

Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly subcutaneous blisibimod missed the primary endpoint of a greater proportion of...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BC Week In Review | Sep 12, 2016
Financial News

Anthera completes private placement of convertible preferred stock and warrants

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif.   Business: Autoimmune, Gastrointestinal, Renal   Date completed: 2016-09-08   Type: Private placement of convertible preferred stock and warrants   Raised: $17 million   Shares: 17,000   Price: $1,000...
Items per page:
1 - 10 of 171